Cel
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical trials on DSM categories which provide a collection of biologically heterogeneous patients. Our broad working hypothesis is that a focus on cross-species endophenotypes, testing in healthy volunteers and finding biologically-homogenous groups of patients will overcome existing limitations in target identification, early triage and clinical trials. To implement this idea six leading European institutions and two SMEs will partner with the EFPIA to: a) develop animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g. cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of fMRI-based endopheno types in genetically-selected healthy volunteers and patients as early and surrogate markers for efficacy; and to combine this with PET approaches for plasma-kinetics to brain-dynamics modelling to provide guidance regarding optimal clinical trial design; and c) identify pharmacogenetic and multi-omic biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for ) targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms; Bayesian analyses) and will
actively collaborate with other ongoing international efforts (esp. the Biomarkers Consortium, NIH).
Dziedzina nauki
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesneurobiologycognitive neuroscience
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicinepsychiatryschizophrenia
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Temat(-y)
Zaproszenie do składania wniosków
IMI-JU-01-2008
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Koordynator
2500 Valby
Dania
Zobacz na mapie
Uczestnicy (19)
WC2R 2LS London
Zobacz na mapie
17177 Stockholm
Zobacz na mapie
CB2 1TN Cambridge
Zobacz na mapie
68159 Mannheim
Zobacz na mapie
28006 Madrid
Zobacz na mapie
M13 9PL Manchester
Zobacz na mapie
CB4 0WS Cambridge
Zobacz na mapie
Zakończenie uczestnictwa
101 Reykjavik
Zobacz na mapie
80333 Muenchen
Zobacz na mapie
Zakończenie uczestnictwa
151 85 Sodertaelje
Zobacz na mapie
RG21 4FA Basingstoke
Zobacz na mapie
2340 Beerse
Zobacz na mapie
4056 Basel
Zobacz na mapie
02200 Espoo
Zobacz na mapie
CT13 9NJ Sandwich
Zobacz na mapie
4070 Basel
Zobacz na mapie
91190 GIF-SUR-YVETTE
Zobacz na mapie
52900 Ramat Gan
Zobacz na mapie
65205 Wiesbaden
Zobacz na mapie